Esclerosis múltiple: diagnóstico diferencial y tratamiento

  1. Alberte Woodward, M. 1
  2. Naveiro Soneira, J. 1
  3. Prieto González, J.M.Ó 1
  1. 1 Servicio de Neurología, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, La Coruña, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Ano de publicación: 2023

Título do exemplar: Enfermedades del sistema nervioso (IX): Enfermedades desmielinizantes

Serie: 13

Número: 78

Páxinas: 4628-4634

Tipo: Artigo

DIALNET GOOGLE SCHOLAR

Outras publicacións en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumo

The diagnostic criteria for multiple sclerosis(MS) are based on the identification of a typical syndrome attributable to the central nervous system, the demonstration of dissemination in space and time, and the absence of a better explanation than MS. This article includes some of the demographic, clinical or paraclinical criteria that should prompt consideration of alternative diagnoses. In addition, the usage of the 18 disease-modifying drugs currently employed is reviewed, including the latest additions (diroximel fumarate, siponimod, ozanimod, ponensimod and ofatumumab), the recent indications in clinical courses other than relapsing-remitting and the symptomatic treatment of the disease.

Referencias bibliográficas

  • Wildner P, Stasiołek M, Matysiak M. Differential diagnosis of multiple sclerosis and other inflammatory CNS diseases. Mult Scler Relat Disord. 2020;37:101452.
  • Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler. 2008;14(9):1157-74.
  • Oh J. Diagnosis of multiple sclerosis. Continuum (Minneap Minn). 2022;28(4):1006-24.
  • Solomon AJ. Diagnosis, differential diagnosis, and misdiagnosis of multiple sclerosis. Continuum (Minneap Minn). 2019;25(3):611-35.
  • Flanagan EP. Neuromyelitis optica spectrum disorder and other non-multiple sclerosis central nervous system inflammatory diseases. Continuum (Minneap Minn). 2019;25(3):815-44.
  • Boski N, Gulati V, Raj R, Gulati P. Multiple sclerosis-minimizing errors in radiological diagnosis. Neurol India. 2021;69(6):1539-46.
  • Gross RH, Corboy JR. Monitoring, switching, and stopping multiple sclerosis disease-modifying therapies. Continuum (Minneap Minn). 2019;25(3):715-35.
  • Hauser SL, Bar Or A, Cohen JA, Comi G, Correale J, Coyle PK. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546-57.
  • Cohen JA, Comi G, Selmaj KW, Bar Or A, Arnold DL, Steinman L. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019;18(11):1021-33.
  • Kappos L, Fox RJ, Burcklen M, Freedman MS, Havrdová EK, Hennessy B. Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM Study: A randomized clinical trial. JAMA Neurol. 2021;78(5):558-67.
  • Signori A, Saccà F, Lanzillo R, Maniscalco GT, Signoriello E, Repice AM. Cladribine vs other drugs in MS: Merging randomized trial with real-life data. Neurol Neuroimmunol Neuroinflamm. 2020;7(6):e878.
  • García Merino JA, Saiz Hinarejos A. Tratamiento para modificar la historia natural de la enfermedad. In: Guía oficial de práctica clínica en esclerosis múltiple. Madrid: Luzán 5; 2014. p. 77-86.
  • Langer Gould AM. Pregnancy and family planning in multiple sclerosis. Continuum (Minneap Minn). 2019;25(3):773-92.
  • Lorefice L, Fenu G, Gerevini S, Frau J, Coghe G, Barracciu MA. PML in a person with multiple sclerosis: Is teriflunomide the felon? Neurology. 2018;90(2):83-5.
  • Naismith RT, Wundes A, Ziemssen T, Jasinska E, Freedman MS, Lembo AJ. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: Results from the randomized, double-blind, Phase III EVOLVE-MS-2 Study. CNS Drugs. 2020;34(2):185-96.
  • Hellwig K, Rog D, McGuigan C, Houtchens MK, Bruen DR, Mokliatchouk O. Interim analysis of pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registry. Neurol Neuroimmunol Neuroinflamm. 2022;9(1):e1114.
  • Bowen JD. Highly aggressive multiple sclerosis. Continuum (Minneap Minn). 2019;25(3):689-714.
  • Kappos L, Bar Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263-73.
  • Morrow SA, Clift F, Devonshire V, Lapointe E, Schneider R, Stefanelli M. Use of natalizumab in persons with multiple sclerosis: 2022 update. Mult Scler Relat Disord. 2022;65:103995.
  • Bernard Valnet R, Koralnik IJ, Du Pasquier R. Advances in treatment of progressive multifocal leukoencephalopathy. Ann Neurol. 2021;90(6):865-73.
  • Gerevini S, Capra R, Bertoli D, Sottini A, Imberti L. Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy. Mult Scler. 2019;25(8):1196-201.
  • Ruck T, Barman S, Schulte Mecklenbeck A, Pfeuffer S, Steffen F, Nelke C. Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity. Brain. 2022;145(5):1711-25.
  • Coles A. Campath, clones and the cause of autoimmunity. Brain. 2022;145(5):1579-80.
  • Nabizadeh F, Pirahesh K, Rafiei N, Afrashteh F, Ahmadabad MA, Zabeti A. Autologous hematopoietic stem-cell transplantation in multiple sclerosis: A systematic review and meta-analysis. Neurol Ther. 2022;(4):1553-69.
  • Burt RK, Han X, Quigley K, Helenowski IB, Balabanov R. Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis. J Neurol. 2022;269(5):2513-26.
  • Cross A, Riley C. Treatment of multiple sclerosis. Continuum (Minneap Minn). 2022;28(4):1025-51.
  • Tobin WO. Management of multiple sclerosis symptoms and comorbidities. Continuum (Minneap Minn). 2019;25(3):753-72.
  • Hernández Pérez MÁ. Tratamiento sintomático de la esclerosis múltiple. In: Guía oficial de práctica clínica en esclerosis múltiple. Madrid: Luzán 5; 2014. p. 87-91.
Fonte de datos: Dialnet